Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 1:154:105510.
doi: 10.1016/j.ejps.2020.105510. Epub 2020 Aug 12.

Biological evaluation and molecular modeling of peptidomimetic compounds as inhibitors for O-GlcNAc transferase (OGT)

Suraby O Albuquerque  1 , Thalita G Barros  2 , Luiza R S Dias  2 , Camilo H da S Lima  3 , Pedro H R de A Azevedo  2 , Luiz A P Flores-Junior  2 , Eldio G Dos Santos  2 , Hector F Loponte  1 , Sergio Pinheiro  4 , Wagner B Dias  1 , Estela M F Muri  2 , Adriane R Todeschini  5
Affiliations

Biological evaluation and molecular modeling of peptidomimetic compounds as inhibitors for O-GlcNAc transferase (OGT)

Suraby O Albuquerque et al. Eur J Pharm Sci. .

Abstract

The vital enzyme O-linked β-N-acetylglucosamine transferase (OGT) catalyzes the O-GlcNAcylation of intracellular proteins coupling the metabolic status to cellular signaling and transcription pathways. Aberrant levels of O-GlcNAc and OGT have been linked to metabolic diseases as cancer and diabetes. Here, a new series of peptidomimetic OGT inhibitors was identified highlighting the compound LQMed 330, which presented better IC50 compared to the most potent inhibitors found in the literature. Molecular modeling study of selected inhibitors into the OGT binding site provided insight into the behavior by which these compounds interact with the enzyme. The results obtained in this study provided new perspectives on the design and synthesis of highly specific OGT inhibitors.

Keywords: Glycosylation; Inhibitors; Molecular docking; Molecular dynamics; Molecular modeling; O-GlcNAc; OGT; Peptidomimetics; Post-translational modification.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest I would like to declare on behalf of my co-authors that the work described was original research that has not been published previously, and not under consideration for publication elsewhere, in whole or in part. I declare that we have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

MeSH terms

LinkOut - more resources